Astellas Gene Therapies Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Astellas Gene Therapies Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 25 May 2018 | Lorem |
| Audentes Therapeutics Phase I/II trial of AT132 in XLMTM leaves experts enthusiastic over efficacy while watchful over safety | 29 Mar 2018 | Hannah Wilgar |
| Audentes Therapeutics’ AT132 Phase I/II ASPIRO trial in XLMTM will continue with low dose for next drug treatment cohort based on safety, efficacy signals, source says | 21 Mar 2018 | Hannah Wilgar |
| Audentes to seek CROs with orphan and gene therapy experience – CMO | 29 May 2014 | Casey McDonald |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer